期刊文献+

舒尼替尼耐药肾癌细胞中circTMBIM6表达变化及其与miR-19a-3p/PPARα轴的调控关系 被引量:1

Expression of circTMBIM6 and its relationship with miR-19a-3p/PPARαaxis in sunitinib-resistant renal carcinoma cells
下载PDF
导出
摘要 目的观察舒尼替尼耐药的肾癌细胞中circTMBIM6表达变化,并探讨其与miR-19a-3p/PPARα轴的关系。方法取舒尼替尼耐药的肾癌细胞A498、Caci-1、780-O,采用qRT-PCR法检测细胞中TMBIM6表达。采用Star⁃base、Targetscan数据库,分别预测miR-19a-3p与circTMBIM6 mRNA的3'非翻译区(3'UTR)和PPARαmRNA的3'UTR是否存在互补结合。构建包含结合位点的野生型和突变型circTMBIM6 mRNA 3'UTR双荧光报告质粒。将circTMBIM6-WT、circTMBIM6-MUT与miR-19a-3p mimics或miR-NC阴性对照共转染至786-O细胞。同时将PPARα-WT,PPARα-MUT与miR-19a-3p mimics或miR-NC阴性对照共转染至786-O细胞,构建野生型和突变型的PPARαmRNA 3'UTR双荧光报告质粒,检测miR-19a-3p对circTMBIM63'UTR和PPARαmRNA 3'UTR荧光素酶报告基因活性的影响。si-circTMBIM6和si-NC+miR-NC阴性对照共转染至A498、Caci-1、780-O细胞,将3种肾癌细胞分为抑表达组、对照组,分别转染si-circTMBIM6和si-NC+miR-NC,采用qPCR法检测三种细胞中miR-19a-3p表达。将三种细胞分为miR-19a-3p过表达组、miR-19a-3p抑表达组和对照组,分别转染miR-19a-3p mimics、miR-19a-3p inhibitor及si-NC+miR-NC阴性对照,采用qRT-PCR法和Westernblotting法检测PPARαmRNA和蛋白表达。将三种肾癌细胞分成阴性对照组、miR-19a-3p抑制组、circTMBIM6抑制组,分别转染si-NC+miR-NC阴性对照、si-NC+miR-19a-3p inhibitor和si-circTMBIM,采用RT-PCR法和Westernblotting法分别检测PPARαmRNA和蛋白表达,进一步验证circTMBIM6通过miR-19a-3p调控PPARα的表达。采用CCK-8实验检测各组细胞增殖抑制率,观察肾癌细胞舒尼替尼耐药中circTMBIM6与miR-19a-3p/PPARα轴的调控作用。结果与正常肾癌细胞相比,舒尼替尼耐药的肾癌细胞circTMBIM6表达均升高(P均<0.01)。生物信息学分析预测显示,miR-19a-3p分别与circTMBIM6的3'UTR以及PPARαmRNA的3'UTR具有潜在互补结合位点。双荧光素酶报告基因活性检测显示,在circTMBIM6野生型3'UTR中,miR-19a-3p mimics组荧光素酶活性低于miR-NC组(P<0.05),但在circTMBIM6突变型3'UTR中,两组荧光素酶活性无明显变化。在三种肾癌细胞A498、Caci-1、780-O中,si-circTMBIM6组miR-19a-3p表达均高于si-NC+miR-NC组(P均<0.05)。三种细胞中,miR-19a-3p抑制组PPARαmRNA和蛋白表达较阴性对照组升高;circTM⁃BIM6抑制组PPARαmRNA和蛋白表达较阴性对照组降低(P均<0.05)。CCK-8实验显示,circTMBIM6抑制组细胞增殖抑制率低于阴性对照组,miR-19a-3p抑制组细胞增殖抑制率高于阴性对照组(P均<0.05)。结论舒尼替尼耐药的肾癌细胞中circTMBIM6表达升高;circTMBIM6通过海绵吸收miR-19a-3p调控PPARα表达,降低RCC对舒尼替尼的敏感性,导致耐药的发生。 Objective To investigate the expression level of circTMBIM6 in sunitinib-resistant renal carcinoma(RCC)cells and to explore its relationship with miR-19a-3p/PPARαaxis.Methods The expression of TMBIM6 in suni⁃tinib-resistant RCC cell lines A498,Caci-1 and 780-O was detected by qRT-PCR.The STARBASE and Target scan data⁃bases were used to predict the complementary binding of miR-19a-3p to the 3'untranslated region(3'UTR)of circTMBIM6 mRNA and the 3'UTR of PPARαmRNA.The wild-type and mutant circTMBIM6 mRNA 3'UTR double fluorescence re⁃porter plasmids containing binding sites were constructed.786-O cells were co-transfected with circTMBIM6-WT,circTM⁃BIM6-MUT,miR-19a-3p mimics,or miR-NC negative control.At the same time,PPARα-WT,PPARα-MUT and miR-19a-3p mimics or miR-NC negative control were co-transfected into 786-O cells to construct the wild-type and mutant PPARαmRNA 3'UTR double fluorescence reporter plasmids.The effects of miR-19a-3p on the activities of circTMBIM63'UTR and PPARαmRNA 3'UTR luciferase reporter gene were detected.The si-circTMBIM6 and si-NC+miR-NC nega⁃tive control were co-transfected into A498,Caci-1 and 780-O cells.The three types of renal carcinoma cells were divided into the si-circTMBIM6(down-regulated group)and si-NC+miR-NC group(control group).The expression of miR-19a-3p in the above three cell lines was detected by qPCR.These three kinds of cells were divided into the miR-19a-3p overex⁃pression group,miR-19a-3p inhibitor group,and control group,which were transfected with miR-19a-3p mimics,miR-19a-3p inhibitor and si-NC+miR-NC negative control,respectively.The expression of PPARαmRNA and protein was de⁃tected by qRT-PCR and Western blotting.These three kinds of renal carcinoma cells were divided into the negative control group,miR-19a-3p inhibitor group,and circTMBIM6 inhibitor group,which were transfected with si-NC+miR-NC nega⁃tive control,si-NC+miR-19a-3p inhibitor,and si-circTMBIM,respectively.RT-PCR and Western blotting were used to detect the expression levels of PPARαmRNA and protein and further to verify that circTMBIM6 regulated the expression of PPARαthrough miR-19a-3p.CCK-8 assay was used to detect the inhibition rate of cell proliferation in each group,and we observed the regulatory effects of circTMBIM6 and miR-19a-3p/PPARαaxis in sunitinib-resistant renal carcinoma cells.Results In comparison with normal RCC cells,the expression level of circTMBIM6 in the sunitinib-resistant RCC cells was up-regulated(all P<0.01).Bioinformatics analysis predicted that miR-19a-3p had potential complementary binding sites with the 3'UTR of circTMBIM6 and the 3'UTR of PPARαmRNA.Dual luciferase reporter gene assay reported that the luciferase activity of the circTMBIM6 wild-type 3'UTR in the miR-19a-3p mimics group was lower than that in the miR-NC group(all P<0.05),but there was no significant change in the luciferase activity of the circTMBIM6 MUT 3'UTR in the miR-19a-3p mimics group and miR-NC group.In these three kinds of RCC cells A498,Caci-1,and 780-O,the ex⁃pression of miR-19a-3p in the si-circTMBIM6 group was higher than that in si-NC+miR-NC group(all P<0.05);the rela⁃tive expression levels of PPARαmRNA and protein in the miR-19a-3p inhibitor group were higher than those in the nega⁃tive control group,and those in the circTMBIM6 inhibitor group were lower than those of the negative control group(all P<0.05).CCK-8 assay showed that the inhibition rate of cell proliferation in the circTMBIM6 inhibitor group was lower than that of the negative control group,and that of the miR-19a-3p inhibitor group was higher than that of negative control group(all P<0.05).Conclusion CircTMBIM6 expression level increases in sunitinib-resistant RCC cells,and circTMBIM6 regulates the expression of PPARαthrough sponge absorption of miR-19a-3p,which reduces the sensitivity of RCC cells to sunitinib and leads to drug resistance.
作者 艾尼瓦尔·艾木都拉 张骥驰 张瑞丽 阿不来提·买买提明 Ainiwaer·Aimudula;ZHANG Jichi;ZHANG Ruili;Abulaiti·Maimaitimimg(Cancer Center,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China;不详)
出处 《山东医药》 CAS 2022年第26期6-11,共6页 Shandong Medical Journal
基金 国家自然科学基金项目(81760452)。
关键词 肾肿瘤 舒尼替尼耐药 circTMBIM6 miR-19a-3p PPARΑ renal carcinoma sunitinib resistance circTMBIM6 miR-19a-3p PPARα
  • 相关文献

参考文献1

二级参考文献5

共引文献3

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部